Japan Generics Makers Turn Attention To Versions Of Cancer Drugs
This article was originally published in PharmAsia News
Several Japan-based makers of generic drugs are focusing increasingly on cancer drugs, many of them recently launching their versions of AstraZeneca's Arimidex (anastrozole) for treating breast cancer.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.